bispecific pan-γδ T cell engager with IL-15 fusion (Tavotek Biotherapeutics)

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug Namebispecific pan-γδ T cell engager with IL-15 fusion (Tavotek Biotherapeutics)

Drug Alias Nameattenuated IL-15 along with the IL-15 receptor α sushi domain as a fusion component on the CD123 bispecific pan γδ T cell engager (Tavotek Biotherapeutics)TAVO317A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagersBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionAnti-CD123CD3 T-cell engagers

TargetsInterleukin-3 receptor subunit alphaT cell surface glycoprotein CD3

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTavotek Biotherapeutics

China Registration ClassN/A

Develop Information

Active CompaniesTavotek Biotherapeutics

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A